Page last updated: 2024-10-29

ketorolac and Body Weight

ketorolac has been researched along with Body Weight in 12 studies

Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

ExcerptRelevanceReference
" Finally, the simultaneous increase in CL and Vss resulted in similar estimates for elimination half-life in both unpaired and paired analysis."6.84Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period. ( Allegaert, K; De Hoon, J; Deprest, J; Kulo, A; Maleškić, S; Smits, A; Van Calsteren, K; Van de Velde, M; Verbesselt, R, 2017)
"Caffeine or ketorolac decrease the risk of retinopathy of prematurity and may act synergistically to improve beneficial effect."3.83Pharmacologic synergism of ocular ketorolac and systemic caffeine citrate in rat oxygen-induced retinopathy. ( Ahmad, T; Aranda, JV; Beharry, KD; Bronshtein, V; Cai, CL; Lazzaro, DR; Sadeh, J; Valencia, GB, 2016)
"Only body weight influenced the PK parameters for R(+) and S(-) ketorolac."3.81The enantioselective population pharmacokinetics of intravenous ketorolac in children using a stereoselective assay suitable for microanalysis. ( Cameron, GA; Engelhardt, T; Hawwa, AF; McLay, JS; Mohammed, BS, 2015)
" Finally, the simultaneous increase in CL and Vss resulted in similar estimates for elimination half-life in both unpaired and paired analysis."2.84Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period. ( Allegaert, K; De Hoon, J; Deprest, J; Kulo, A; Maleškić, S; Smits, A; Van Calsteren, K; Van de Velde, M; Verbesselt, R, 2017)
"Ketorolac was administered to 11."1.48Pain Management for Nonsyndromic Craniosynostosis: Adequate Analgesia in a Pediatric Cohort? ( Cho, R; Dorafshar, AH; Faateh, M; Kattail, D; Lopez, J; Macmillan, A; Musavi, L; Pedreira, R, 2018)
" The relationship between the main pharmacokinetic parameters [viz."1.37Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach. ( Gilibili, RR; Mullangi, R; Srinivas, NR, 2011)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (25.00)18.2507
2000's2 (16.67)29.6817
2010's7 (58.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hennig, R1
Albawardi, A1
Almarzooqi, S1
Haneefa, S1
Imbaraj, E1
Zaaba, NE1
Nemmar, A1
Subramanya, S1
Maruta, H1
Adrian, TE1
Kattail, D1
Macmillan, A1
Musavi, L1
Pedreira, R1
Faateh, M1
Cho, R1
Lopez, J1
Dorafshar, AH1
Pezhouman, A1
Cao, H1
Fishbein, MC1
Belardinelli, L1
Weiss, JN1
Karagueuzian, HS1
Moradi, A1
Kheirollahkhani, Y1
Fatahi, P1
Abdollahifar, MA1
Amini, A1
Naserzadeh, P1
Ashtari, K1
Ghoreishi, SK1
Chien, S1
Rezaei, F1
Fridoni, M1
Bagheri, M1
Taheri, S1
Bayat, M1
Cerreta, AJ1
Masterson, CA1
Lewbart, GA1
Dise, DR1
Papich, MG1
Schiegerl, LJ1
Karttunen, AJ1
Klein, W1
Fässler, TF1
Persson, I1
Halim, J1
Lind, H1
Hansen, TW1
Wagner, JB1
Näslund, LÅ1
Darakchieva, V1
Palisaitis, J1
Rosen, J1
Persson, POÅ1
Mohammed, BS1
Engelhardt, T1
Hawwa, AF1
Cameron, GA1
McLay, JS1
Aranda, JV1
Cai, CL1
Ahmad, T1
Bronshtein, V1
Sadeh, J1
Valencia, GB1
Lazzaro, DR1
Beharry, KD1
Kulo, A1
Smits, A1
Maleškić, S1
Van de Velde, M1
Van Calsteren, K1
De Hoon, J1
Verbesselt, R1
Deprest, J1
Allegaert, K1
Gilibili, RR1
Mullangi, R1
Srinivas, NR1
Yaksh, TL1
Horais, KA1
Tozier, N1
Rathbun, M1
Richter, P1
Rossi, S1
Grafe, M1
Tong, C1
Meschter, C1
Cline, JM1
Eisenach, J1
Hsieh, YC1
Liang, WY1
Tsai, SK1
Wong, CS1
Davis, CP1
Torre, PR1
Schafer, NC1
Dave, B1
Bass, B1
Parke, TJ1
Lowson, SM1
Uncles, DR1
Daughtery, MO1
Sitzman, BT1
Ho, ML1
Chang, JK1
Wang, GJ1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections: a Prospective Double-Blinded Randomized Trial[NCT04895280]Phase 4400 participants (Anticipated)Interventional2024-04-30Not yet recruiting
Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial[NCT04115644]Phase 482 participants (Actual)Interventional2017-05-01Terminated (stopped due to Covid-19 and we failed to submit annual report for 2017 and 2018)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Visual Analog Scale

Pain as measured by the Visual Analog Scale after first injection. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Baseline - immediately after the injection

Interventionscore on a scale (Mean)
Group 1 (Control)3.197
Group 2 (Ketorolac)3.577
Group 3 (Kenalog)3.677

Visual Analog Scale

Pain as measured by the Visual Analog Scale prior to first injection. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Baseline - pre-injection

Interventionscore on a scale (Mean)
Group 1 (Control)5.77
Group 2 (Ketorolac)4.57
Group 3 (Kenalog)4.67

Visual Analog Scale

Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Day 2

Interventionscore on a scale (Mean)
Group 1 (Control)2.347
Group 2 (Ketorolac)2.837
Group 3 (Kenalog)2.67

Visual Analog Scale

Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 1

Interventionscore on a scale (Mean)
Group 1 (Control)3.397
Group 2 (Ketorolac)3.7
Group 3 (Kenalog)3.257

Visual Analog Scale

Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 12

Interventionscore on a scale (Mean)
Group 1 (Control)3.447
Group 2 (Ketorolac)1.417
Group 3 (Kenalog)2.027

Visual Analog Scale

Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 2

Interventionscore on a scale (Mean)
Group 1 (Control)3.547
Group 2 (Ketorolac)2.67
Group 3 (Kenalog)2.57

Visual Analog Scale

Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 4

Interventionscore on a scale (Mean)
Group 1 (Control)3.547
Group 2 (Ketorolac)2.67
Group 3 (Kenalog)2.317

Visual Analog Scale

Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 6

Interventionscore on a scale (Mean)
Group 1 (Control)3.357
Group 2 (Ketorolac)2.757
Group 3 (Kenalog)2.687

Trials

3 trials available for ketorolac and Body Weight

ArticleYear
Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period.
    Bosnian journal of basic medical sciences, 2017, Feb-21, Volume: 17, Issue:1

    Topics: Administration, Intravenous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Case-Contr

2017
Ketorolac as a rapid and effective treatment of migraine headache: evaluations by patients.
    The American journal of emergency medicine, 1993, Volume: 11, Issue:6

    Topics: Acute Disease; Adult; Analgesics; Body Weight; Emergency Service, Hospital; Female; Humans; Injectio

1993
Pre-emptive versus post-surgical administration of ketorolac for hysterectomy.
    European journal of anaesthesiology, 1995, Volume: 12, Issue:6

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic

1995

Other Studies

9 other studies available for ketorolac and Body Weight

ArticleYear
1,2,3-Triazolyl ester of ketorolac (15K), a potent PAK1 blocker, inhibits both growth and metastasis of orthotopic human pancreatic cancer xenografts in mice.
    Drug discoveries & therapeutics, 2019, Nov-14, Volume: 13, Issue:5

    Topics: Animals; Body Weight; Cell Line, Tumor; Cell Proliferation; Esters; Hemodynamics; Humans; Inhibitory

2019
Pain Management for Nonsyndromic Craniosynostosis: Adequate Analgesia in a Pediatric Cohort?
    The Journal of craniofacial surgery, 2018, Volume: 29, Issue:5

    Topics: Age Factors; Analgesia; Analgesics, Non-Narcotic; Analgesics, Opioid; Body Weight; Child, Preschool;

2018
    Journal of heart health, 2018, Apr-25, Volume: 4, Issue:1

    Topics: Analgesia; Analgesics; Analysis of Variance; Animals; Bacteria; Body Weight; Chromatography, High Pr

2018
The enantioselective population pharmacokinetics of intravenous ketorolac in children using a stereoselective assay suitable for microanalysis.
    The Journal of pharmacy and pharmacology, 2015, Volume: 67, Issue:9

    Topics: Administration, Intravenous; Adolescent; Body Weight; Child; Child, Preschool; Female; Humans; Infan

2015
Pharmacologic synergism of ocular ketorolac and systemic caffeine citrate in rat oxygen-induced retinopathy.
    Pediatric research, 2016, Volume: 80, Issue:4

    Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Apyrase; Arteries; Body Weight;

2016
Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach.
    European journal of drug metabolism and pharmacokinetics, 2011, Volume: 36, Issue:2

    Topics: Algorithms; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Brain; Cerebrovascular Ci

2011
Intrathecal ketorolac in dogs and rats.
    Toxicological sciences : an official journal of the Society of Toxicology, 2004, Volume: 80, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Dogs; Dose-Response Relationship, Dru

2004
Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats.
    Anesthesia and analgesia, 2005, Volume: 100, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Injections, Spinal; Ketorolac; Male;

2005
Effects of ketorolac on bone repair: A radiographic study in modeled demineralized bone matrix grafted rabbits.
    Pharmacology, 1998, Volume: 57, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bone Matrix

1998
Effects of ketorolac on bone repair: A radiographic study in modeled demineralized bone matrix grafted rabbits.
    Pharmacology, 1998, Volume: 57, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bone Matrix

1998
Effects of ketorolac on bone repair: A radiographic study in modeled demineralized bone matrix grafted rabbits.
    Pharmacology, 1998, Volume: 57, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bone Matrix

1998
Effects of ketorolac on bone repair: A radiographic study in modeled demineralized bone matrix grafted rabbits.
    Pharmacology, 1998, Volume: 57, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bone Matrix

1998